Floatz Rating
B63/100
Confidence
Indicative
Sponsor
University of Hawaii
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07075120CT.gov Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer | — | Recruiting | — | — | — |
NCT07560488CT.gov Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT07422753CT.gov A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC | — | Recruiting | — | — | — |
NCT07487662CT.gov TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk | — | Not Yet Recruiting | — | — | — |
NCT07291076CT.gov A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) | — | Recruiting | — | — | — |
NCT07166406CT.gov Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial | — | Recruiting | — | — | — |
NCT07482059CT.gov A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT07227012CT.gov Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. | — | Recruiting | — | — | — |
NCT07176650CT.gov Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT07147101CT.gov Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment | — | Recruiting | — | — | — |
Show 18 more trialsShow fewer
NCT06841185CT.gov A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT06362369CT.gov A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | — | Recruiting | — | — | — |
NCT05909995CT.gov Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors | — | Terminated | — | — | — |
NCT05665348CT.gov Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy | — | Completed | — | — | — |
NCT05199285CT.gov A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab | — | Terminated | — | — | — |
NCT05220722CT.gov Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors | — | Terminated | — | — | — |
NCT05302921CT.gov Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | — | Completed | — | — | — |
NCT05176483CT.gov Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors | — | Recruiting | — | — | — |
NCT04823403CT.gov Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT04340193CT.gov A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer | — | Completed | — | — | — |
NCT04472767CT.gov Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT04039607CT.gov A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma | — | Active Not Recruiting | — | — | — |
NCT03752398CT.gov A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) | — | Completed | — | — | — |
NCT03682276CT.gov Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT03510871CT.gov Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC) | — | Completed | — | — | — |
NCT03222076CT.gov Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer | — | Completed | — | — | — |
NCT03203304CT.gov Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer | — | Terminated | — | — | — |
NCT01658878CT.gov An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatocellular Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ipilimumab (this asset) | University of Hawaii | P3 | B · 63 |
| Adefovir | Bukwang Pharmaceutical | P4 | BBB |
| Huaier Granule | Tongji Hospital | P4 | BBB |
| Fluorouracilum | Li Qiang | P4 | BBB |
| Oxaliplatin | Li Qiang | P4 | BBB |
| Theprubicin | RWTH Aachen University | P4 | BB |
| Adriamycin | VA Office of Research and Development | P4 | BB |
| nrt6003 | Second Affiliated Hospital of Guangzhou Medical University | P3 | BB |
| Epirubicin | Fudan University | P4 | BB |
+42 more in the Hepatocellular Carcinoma cohort
Other indications for Ipilimumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Neoplasm | — | P3 | BB · 71 |
| Melanoma | — | P4 | BB · 69 |
| Cutaneous Melanoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ipilimumab in Hepatocellular Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ipilimumab-hepatocellular-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →